Sarepta Therapeutics Announces Third Quarter 2020 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Sarepta Therapeutics (SRPT) Tops Q3 EPS by 29c
November 5, 2020 6:03 PM ESTSarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of ($1.42), $0.29 better than the analyst estimate of ($1.71). Revenue for the quarter came in at $143.92 million versus the consensus estimate of $137.43 million.
Even as the pandemic created challenges throughout the third quarter, I am pleased to report that the Sarepta team was able to continue to serve... More
